Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 361

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 361
---
 to other available therapies and product candidates, including any new products that may be approved or other product candidates being investigated for the indications we are investigating; |

| • |     | the ability to recruit clinical study investigators with the appropriate competencies and experience; |

| • |     | clinicians’ willingness to screen their patients for biomarkers to indicate which patients may be eligible 
 for enrollment in our clinical trials;                                                                     |

| • |     | patient referral practices of physicians; |

| • |     | the ability to obtain and maintain patient consents; |

| • |     | the ability to monitor patients adequately during and after treatment; |

| • |     | proximity and availability of clinical trial sites for prospective patients; and |

| • |     | factors we may not be able to control, such as current or potential pandemics that may limit patients, principal 
 investigators or staff or clinical site availability (e.g., the COVID-19 pandemic).                              |

Our inability to enroll a sufficient number of patients for our clinical trials could result in significant delays or may require us to abandon one or more clinical trials altogether. Furthermore, any negative results we may report - 250 -

in clinical trials of FYARRO or any future product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials we are conducting. Similarly, negative
results reported by our competitors about their drug candidates may negatively affect patient recruitment in our clinical trials. Enrollment delays in our clinical trials may result in increased development costs for FYARRO and any other product
candidates that we may develop in the future and jeopardize our ability to obtain regulatory approval for the sale of FYARRO in additional indications or any future product candidates. Furthermore, even if we are able to enroll a sufficient number
of patients for our clinical trials, there is a risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, may not survive the full terms of the clinical trials.
As a result, we may have difficulty maintaining participation in our clinical trials through the treatment and any follow-up periods. In addition, we rely on clinical trial sites to ensure timely conduct of
our clinical trials and, while we have entered into agreements governing their services, we are limited in our ability to compel their actual performance.

We may develop product candidates in combination with other therapies, which exposes us to additional risks.

We may develop product candidates, in combination with one or more currently approved or unapproved therapies to treat cancer or other diseases.